HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]) from CSL Behring – a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prevention of HAE attacks in adolescent and adult patients – is now available in all of Canada.
“As a physician that treats this disease, I’m pleased to have HAEGARDA available for patients across Canada. HAEGARDA represents another needed therapeutic advancement for the prevention of HAE as the only Subcutaneous C1 Inhibitor for preventative therapy approved in Canada”, says Dr. Stephen D Betschel, Clinical Immunologist and Allergist, St. Michael’s Hospital, Toronto.
HAE Canada President, Jacquie Badiou, COO, Daphne Dumbrille, and the Board of Directors, are excited that at long last, HAEGARDA is now equally available, without restrictions, to adolescent and adult HAE patients across Canada. This represents yet another milestone for the advancement of care for Canadian HAE patients who need a subcutaneous C1 esterase inhibitor therapy.
CSL Behring Canada also assists patients to get access to training for the administration of HAEGARDA via the CSL Behring PLUS+ program that offers services and educational materials. Patients can ask their healthcare professionals to enroll them in the program at any time.
(Source: CSL Behring Canada)